The strong association between HOXA9 overexpression and development of AML has encouraged us to determine its expression in CML at diagnosis to determine its proportion among Egyptian patients and to evaluate its relation with BCR-ABL expression and the clinical significance of such expression in disease aggression and patient survival. The gene discussed is HOXA9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.